Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Annals of Internal Medicine

• Publication date

  2009-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-150-6-200903170-00006PMID 19293071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction

  2009cited by this paper
• Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk

  2008cited by this paper
• Aspirin dose for the prevention of cardiovascular disease: a systematic review.

  2007cited by this paper
• The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients

  2007cited by this paper
• Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review.

  2007cited by this paper
• Bleeding as a predictor of mortality risk.

  2006cited by this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention)

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers

  2006cited by this paper
• Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease.

  2006cited by this paper
• Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System.

  2006cited by this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cited by this paper
• Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications

  2006cited by this paper
• Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.

  2005cited by this paper
• Aspirin dose and six-month outcome after an acute coronary syndrome.

  2004cited by this paper
• Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

  2004cited by this paper
• Antiplatelet Effect of Aspirin in Patients With Cerebrovascular Disease

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease

  2003cited by this paper
• Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study

  2003cited by this paper
• Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002; 105: 1650- 1655.

  2002cited by this paper
• Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.

  2000cited by this paper
• Prophylactic aspirin and risk of peptic ulcer bleeding

  1995cited by this paper
• Dose Effects of Aspirin on Gastric Prostaglandins and Stomach Mucosal Injury

  1994cited by this paper
• Evaluation of Thromboxane Production and Complement Activation During Myocardial Ischemia in Patients With Angina Pectoris

  1991cited by this paper
• Clinical pharmacology of platelet cyclooxygenase inhibition.

  1985cited by this paper
• Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.

  1983cited by this paper
• Aspirin in the treatment of vascular diseases.

  1949cited by this paper

• Efficacy and safety of clopidogrel and aspirin in patients with chronic coronary syndrome: a systematic review and meta-analysis.

  2026cites this paper
• Management of Anticoagulant and Antiplatelet Therapy in Elective Degenerative Lumbosacral Spine Surgery: A Clinical Study on 578 Elderly Patients.

  2025cites this paper
• Comparative evaluation of surgicel and gelfoam in controlling post-extraction bleeding in patients on anticoagulant therapy: a clinical study

  2025cites this paper
• Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription in the treatment of polycythemia vera with heat toxin and blood stasis syndrome.

  2025cites this paper
• A graph attention–based deep learning network for predicting biotech–small-molecule drug interactions

  2025cites this paper
• [Guidelines for the management of non-ST elevation acute coronary syndromes (2024)].

  2024cites this paper
• Hat die ASS-Desaktivierung in Zeiten von Biologika noch einen Stellenwert bei chronischer Rhinosinusitis mit nasaler Polyposis?

  2024cites this paper
• Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?

  2023cites this paper
• Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque—Provided by the Society for the Prevention of Symptomatic Heart Disease

  2022cites this paper
• The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study

  2022cites this paper
• ASPC Manual of Preventive Cardiology

  2021influential citation
• CLINICAL OUTCOMES OF FIBRINOLYTIC THERAPY FOR PREHOSPITAL TREATMENT OF ACUTE MYOCARDIAL INFARCTION

  2021cites this paper
• Beta-blockers in patients without heart failure after myocardial infarction.

  2021cites this paper
• A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease

  2021influential citation
• Surgery for Coagulopathy-Related Intracerebral Hemorrhage: Craniotomy vs. Minimally Invasive Neurosurgery

  2021cites this paper
• The Future of Aspirin Therapy in Cardiovascular Disease.

  2021cites this paper
• An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS)

  2020cites this paper
• Modern Management of ST-Segment Elevation Myocardial Infarction.

  2020cites this paper
• The impact of frailty on epistaxis admission, a retrospective cohort study

  2020cites this paper
• A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis.

  2020cites this paper
• Antiplatelet Therapy

  2020cites this paper
• The emergent phenomenon of aspirin resistance: insights from genetic association studies.

  2020cites this paper
• Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50 (ED50).

  2019cites this paper
• Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.

  2019cites this paper
• P2Y12 Antagonists

  2019cites this paper
• Previous Antithrombotic Therapy, Particularly Anticoagulant, Is Associated with Unfavorable Outcomes in Patients with Primary Spontaneous Intracerebral Hemorrhage Receiving Craniotomy: A Nationwide Population-Based Cohort Study.

  2019cites this paper
• Antithrombotic dose: some observations from published clinical trials.

  2019cites this paper
• Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS

  2018cites this paper
• Adverse Effect of Antithrombotic Medications on Bleeding Events and Comparison of Antithrombotic Agents in Hemodialysis Patients

  2018cites this paper
• How aspirin prevents cardiovascular diseases

  2018cites this paper
• Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease

  2018cites this paper
• Anti-inflammatory effects of anti-platelet drugs : implications for atherosclerosis

  2018cites this paper
• Aspirin for Preventing Hemodialysis-associated Chronic Hepatitis C Infections

  2018cites this paper
• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]

  2018cites this paper
• 24 – Managing Chronic Coronary Artery Disease in Patients with Diabetes

  2018cites this paper
• The art of delivering evidence-based dual antiplatelet therapy.

  2018cites this paper
• 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

  2018cites this paper
• An emerging consensus

  2017cites this paper
• Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease

  2017cites this paper
• 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

  2017cites this paper
• Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence

  2017cites this paper
• Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.

  2017cites this paper
• Cardiovascular events after discontinuation of low-dose aspirin.

  2017cites this paper
• The impact of aspirin and anticoagulant usage on outcomes after aneurysmal subarachnoid hemorrhage: a Nationwide Inpatient Sample analysis.

  2017cites this paper
• European Society of Cardiology and American College of Cardiology STEMI Guidelines

  2017cites this paper
• 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

  2017cites this paper
• One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper

  2017cites this paper
• Modern principles of antiplatelet antithrombotic therapy

  2017cites this paper
• Retroperitoneal Bleed with Ticagrelor Administration Following Fibrinolytic Therapy in Acute ST-Elevation Myocardial Infarction

  2016cites this paper
• Anti-platelet drugs attenuate the expansion of circulating CD14 high CD16 1 monocytes under pro-inflammatory conditions

  2016cites this paper
• Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events

  2016cites this paper
• Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.

  2016cites this paper
• Anti-platelet drugs attenuate the expansion of circulating CD14 high CD16 1 monocytes under pro-inflammatory conditions

  2016cites this paper
• Aspirin and the Prevention of Colorectal Cancer

  2016cites this paper
• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2016cites this paper
• Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.

  2016cites this paper
• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2016influential citation
• [Antiplatelet therapy in cardiology].

  2016cites this paper
• 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2016cites this paper
• Anti-platelet drugs attenuate the expansion of circulating CD14highCD16+ monocytes under pro-inflammatory conditions

  2016cites this paper
• The Role of Platelet and its Interaction with Aspirin

  2016cites this paper
• Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events

  2016cites this paper
• Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study

  2015cites this paper
• European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer.

  2015cites this paper
• Exploring PLATO-USA paradox and CURRENT-OASIS 7 trials reveals the benefit of higher aspirin dose.

  2015cites this paper
• Recent advances in the diagnosis and treatment of acute myocardial infarction.

  2015cites this paper
• Concomitant medication use and its implications on the hazard pattern in pharmacoepidemiological studies: example of antidepressants, benzodiazepines and fracture risk

  2015cites this paper
• New approaches to inhibiting platelets and coagulation.

  2015cites this paper
• Endothelial dysfunction in young healthy men is associated with aspirin resistance.

  2015cites this paper
• ASA failure

  2014cites this paper
• Impact of Platelet Transfusion on Survival of Patients with Intracerebral Hemorrhage after Administration of Anti-Platelet Agents at a Tertiary Emergency Center

  2014cites this paper
• Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease

  2014cites this paper
• Platelet Activation Through the Efficacy of Aspirin in Congenital Heart Disease Patients Undergoing Transcatheter Closure of Atrial Septal Defects or Ventricular Septal Defects

  2014cites this paper
• Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis.

  2014cites this paper
• Platelet‐reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta‐analysis

  2014cites this paper
• Highlights From the 2013 ACCF/AHA Guidelines for the Management of ST‐Elevation Myocardial Infarction and Beyond

  2014cites this paper
• Recent advances in antithrombotic therapy after acute coronary syndrome

  2014cites this paper
• Neurologic complications of myocardial infarction.

  2014cites this paper
• Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis

  2014cites this paper
• Improving quality of fall prevention and management in elderly patients using information technology: The impact of computerized decision support

  2014cites this paper
• Invasive Therapy for Women Presenting with Acute Coronary Syndromes

  2014cites this paper
• Antiplatelet response to aspirin and clopidogrel in patients with coronary artery disease undergoing percutaneous coronary intervention

  2014cites this paper
• the American Heart Association and American College of Cardiology Foundation Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With

  2014cites this paper
• Task Force on Practice Guidelines A Report of the American College of Cardiology Foundation/American Heart Association 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction:

  2014cites this paper
• Using antiplatelet agents in clinical practice

  2014cites this paper
• Antithrombotic Issues in Women

  2014cites this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

  2014cites this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• Effect of Antiplatelet Therapy on Coronary Heart Disease Risk in Patients

  2014cites this paper
• Management of Cardiovascular Disease in Women

  2014cites this paper
• 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cites this paper
• Antiplatelet agents for chronic kidney disease.

  2013cites this paper
• Prognosis after cerebral ischaemia of arterial origin: clinical characteristics and genetic information

  2013cites this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cites this paper
• Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy.

  2013cites this paper
• The association between low‐dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study

  2013cites this paper
• An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations.

  2013cites this paper
• ADP Receptor Antagonists

  2013cites this paper